Grifols Slows Alzheimer’s Progression With Plasmapheresis
Executive Summary
Plasmapheresis with Grifols’ Albutein could provide a new treatment avenue for Alzheimer’s disease, but more data will be needed to convince.
You may also be interested in...
COVID-19 Made Its Mark On the R&D Pipeline And Novel Drug Launches In 2020
A new analysis reveals the impact of the coronavirus pandemic on pharma R&D in 2020 in two quarters: the total size of the pipeline and in the number of novel products launched in their first markets.
Worldwide Novel Drug Launches Soared Amid Pandemic
The number of novel products launched in their first markets in 2020 hit record heights in spite of – and in part buoyed by – the pandemic, with an exceptional year for infectious diseases therapeutics and vaccines.
COVID-19 Accounts For Most Of 2020’s Pharma Pipeline Growth
The impact of the coronavirus pandemic on the size of the pharma R&D pipeline in 2020 could be felt in a number of ways.